Wall Street brokerages expect UROGEN PHARMA (NASDAQ:URGN) to post $7.67 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for UROGEN PHARMA’s earnings, with estimates ranging from $7.50 million to $8.00 million. The company is expected to report its next earnings report on Monday, November 13th.

According to Zacks, analysts expect that UROGEN PHARMA will report full year sales of $7.67 million for the current year, with estimates ranging from $7.50 million to $8.00 million. For the next financial year, analysts expect that the firm will report sales of $0.00 per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover UROGEN PHARMA.

URGN has been the subject of several recent analyst reports. Zacks Investment Research downgraded UROGEN PHARMA from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Oppenheimer Holdings, Inc. set a $32.00 price target on UROGEN PHARMA and gave the stock a “buy” rating in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. UROGEN PHARMA has a consensus rating of “Buy” and an average price target of $26.00.

Several large investors have recently bought and sold shares of URGN. FMR LLC bought a new position in shares of UROGEN PHARMA during the second quarter worth about $13,892,000. Hillhouse Capital Management Ltd. bought a new position in shares of UROGEN PHARMA during the second quarter worth about $6,363,000. Jennison Associates LLC bought a new position in shares of UROGEN PHARMA during the second quarter worth about $3,168,000. Wildcat Capital Management LLC bought a new position in shares of UROGEN PHARMA during the second quarter worth about $2,439,000. Finally, Menora Mivtachim Holdings LTD. bought a new position in shares of UROGEN PHARMA during the second quarter worth about $2,331,000. Institutional investors and hedge funds own 36.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “$7.67 Million in Sales Expected for UROGEN PHARMA (URGN) This Quarter” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/7-67-million-in-sales-expected-for-urogen-pharma-urgn-this-quarter/1618375.html.

Shares of UROGEN PHARMA (NASDAQ URGN) traded down 3.61% during midday trading on Thursday, reaching $29.36. The company’s stock had a trading volume of 39,729 shares. The company’s market cap is $381.97 million. UROGEN PHARMA has a 12 month low of $13.01 and a 12 month high of $33.77. The stock has a 50-day moving average of $26.88 and a 200 day moving average of $20.57.

About UROGEN PHARMA

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on UROGEN PHARMA (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for UROGEN PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UROGEN PHARMA and related companies with Analyst Ratings Network's FREE daily email newsletter.